These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 12211096

  • 1. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
    Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T.
    Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable.
    Medori R, Mannaert E, Gründer G.
    Eur Neuropsychopharmacol; 2006 May; 16(4):233-40. PubMed ID: 16326078
    [Abstract] [Full Text] [Related]

  • 6. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S.
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Markers of D(2) and D(3) receptor activity in vivo: PET scan and prolactin.
    Thomasson-Perret N, Pénélaud PF, Théron D, Gouttefangeas S, Mocaër E.
    Therapie; 2008 Mar; 63(3):237-42. PubMed ID: 18718212
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L.
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK, Brennum LT, Kreilgaard M.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):318-27. PubMed ID: 18325493
    [Abstract] [Full Text] [Related]

  • 14. Neuroleptic malignant syndrome with risperidone.
    Gleason PP, Conigliaro RL.
    Pharmacotherapy; 1997 Apr 28; 17(3):617-21. PubMed ID: 9165568
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
    Knable MB, Heinz A, Raedler T, Weinberger DR.
    Psychiatry Res; 1997 Sep 29; 75(2):91-101. PubMed ID: 9351491
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
    Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF.
    Clin Pharmacokinet; 2014 Jun 29; 53(6):533-43. PubMed ID: 24464285
    [Abstract] [Full Text] [Related]

  • 18. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y.
    Int J Neuropsychopharmacol; 2004 Mar 29; 7(1):19-26. PubMed ID: 14764214
    [Abstract] [Full Text] [Related]

  • 19. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
    Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S.
    Life Sci; 1995 Mar 29; 57(10):PL103-7. PubMed ID: 7543969
    [Abstract] [Full Text] [Related]

  • 20. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
    Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR.
    Ther Drug Monit; 2012 Apr 29; 34(2):182-7. PubMed ID: 22377743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.